io9
The AI engine Fit Assessment
Betaio9 leverages machine learning to enhance cancer diagnostics and therapeutics, focusing on biomarker identification and pattern discovery.
Blurb
Operator of a pathology therapeutic selection platform intended to detect genomic biomarkers and make access to possible treatments.
HQ Location
United States
Founded
2021
Employees
2
Total funding raised
Not available
Last Funding Event
Not available
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
- Biomarker Identification
Operator of a pathology therapeutic selection platform intended to detect genomic biomarkers and make access to possible treatments. The company's platform specializes in providing cancer diagnosis, new targets for cancer treatment, and new therapeutic approaches, enabling researchers to make cancer detection and care more equitable around the globe.